Global Gastrointestinal Stromal Tumors Therapeutics Market 2019-2023
SKU ID : TNV-14326714 | Publishing Date : 17-May-2019 | No. of pages : 128
Detailed TOC of Global Gastrointestinal Stromal Tumors Therapeutics Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY ROA
Market segmentation by RoA
Comparison by RoA
Oral - Market size and forecast 2018-2023
Parenteral - Market size and forecast 2018-2023
Market opportunity by RoA
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 14: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Bayer AG
Bristol-Myers Squibb Co.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
PART 15: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global gastrointestinal stromal tumors therapeutics market pipeline: Overview
Exhibit 18: Global gastrointestinal stromal tumors therapeutics market pipeline: Snapshot
Exhibit 19: RoA - Market share 2018-2023 (%)
Exhibit 20: Comparison by RoA
Exhibit 21: Oral - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Oral - Year-over-year growth 2019-2023 (%)
Exhibit 23: Parenteral - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Parenteral - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by RoA
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Global rise in geriatric population
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Bayer AG - Vendor overview
Exhibit 51: Bayer AG - Business segments
Exhibit 52: Bayer AG - Organizational developments
Exhibit 53: Bayer AG - Geographic focus
Exhibit 54: Bayer AG - Segment focus
Exhibit 55: Bayer AG - Key offerings
Exhibit 56: Bayer AG - Key customers
Exhibit 57: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 58: Bristol-Myers Squibb Co. - Business segments
Exhibit 59: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 60: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 61: Bristol-Myers Squibb Co. - Key offerings
Exhibit 62: Bristol-Myers Squibb Co. - Key customers
Exhibit 63: Merck & Co. Inc. - Vendor overview
Exhibit 64: Merck & Co. Inc. - Business segments
Exhibit 65: Merck & Co. Inc. - Organizational developments
Exhibit 66: Merck & Co. Inc. - Geographic focus
Exhibit 67: Merck & Co. Inc. - Segment focus
Exhibit 68: Merck & Co. Inc. - Key offerings
Exhibit 69: Merck & Co. Inc. - Key customers
Exhibit 70: Novartis AG - Vendor overview
Exhibit 71: Novartis AG - Business segments
Exhibit 72: Novartis AG - Organizational developments
Exhibit 73: Novartis AG - Geographic focus
Exhibit 74: Novartis AG - Segment focus
Exhibit 75: Novartis AG - Key offerings
Exhibit 76: Novartis AG - Key customers
Exhibit 77: Pfizer Inc. - Vendor overview
Exhibit 78: Pfizer Inc. - Business segments
Exhibit 79: Pfizer Inc. - Organizational developments
Exhibit 80: Pfizer Inc. - Geographic focus
Exhibit 81: Pfizer Inc. - Segment focus
Exhibit 82: Pfizer Inc. - Key offerings
Exhibit 83: Pfizer Inc. - Key customers
Exhibit 84: Validation techniques employed for market sizing
Exhibit 85: Definition of market positioning of vendors
Keyplayers in Global Gastrointestinal Stromal Tumors Therapeutics Market 2019-2023
Bayer AGBristol-Myers Squibb Co.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.